Authors have examined the effects of combined treatment with arginine deprivation therapy and cyclin-dependent kinase (CDK) inhibitors in ASS1-deficient glioblastoma cells due to the CDK activity in a variety of cancers [41]. The gene discussed is ASS1; the disease is glioblastoma.